These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

421 related articles for article (PubMed ID: 24390940)

  • 1. Carfilzomib-associated tumor lysis syndrome.
    Shely RN; Ratliff PD
    Pharmacotherapy; 2014 May; 34(5):e34-7. PubMed ID: 24390940
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Carfilzomib-induced tumor lysis syndrome in relapsed multiple myeloma: a report of two cases.
    Terzi Demirsoy E; Birtas Atesoglu E; Eren N; Gedük A; Mehtap O; Tarkun P; Hacıhanefioğlu A
    Tumori; 2019 Dec; 105(6):NP24-NP27. PubMed ID: 30580656
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Carfilzomib Induced Tumor Lysis Syndrome and Other Adverse Events.
    Sandy EB; Weerasinghe C; Terjanian T
    J Pharm Pract; 2020 Apr; 33(2):213-216. PubMed ID: 30278813
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Tumor lysis syndrome in patients with light chain multiple myeloma: report of two cases.
    Chang H; Lee SY; Tang TC
    Chang Gung Med J; 2011; 34(6 Suppl):70-5. PubMed ID: 22490464
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Carfilzomib: a second-generation proteasome inhibitor for the treatment of relapsed and refractory multiple myeloma.
    Thompson JL
    Ann Pharmacother; 2013 Jan; 47(1):56-62. PubMed ID: 23300152
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Tumor lysis syndrome after bortezomib therapy for plasma cell leukemia.
    Jaskiewicz AD; Herrington JD; Wong L
    Pharmacotherapy; 2005 Dec; 25(12):1820-5. PubMed ID: 16305302
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Acute tumor lysis syndrome in solid tumors--a case report and review of the literature.
    Baeksgaard L; Sørensen JB
    Cancer Chemother Pharmacol; 2003 Mar; 51(3):187-92. PubMed ID: 12655435
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Management of Carfilzomib-Associated Cardiac Adverse Events.
    Mikhael J
    Clin Lymphoma Myeloma Leuk; 2016 May; 16(5):241-5. PubMed ID: 26907720
    [TBL] [Abstract][Full Text] [Related]  

  • 9. U.s. Food and Drug Administration approval: carfilzomib for the treatment of multiple myeloma.
    Herndon TM; Deisseroth A; Kaminskas E; Kane RC; Koti KM; Rothmann MD; Habtemariam B; Bullock J; Bray JD; Hawes J; Palmby TR; Jee J; Adams W; Mahayni H; Brown J; Dorantes A; Sridhara R; Farrell AT; Pazdur R
    Clin Cancer Res; 2013 Sep; 19(17):4559-63. PubMed ID: 23775332
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Phase I study of 30-minute infusion of carfilzomib as single agent or in combination with low-dose dexamethasone in patients with relapsed and/or refractory multiple myeloma.
    Papadopoulos KP; Siegel DS; Vesole DH; Lee P; Rosen ST; Zojwalla N; Holahan JR; Lee S; Wang Z; Badros A
    J Clin Oncol; 2015 Mar; 33(7):732-9. PubMed ID: 25225420
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Carfilzomib: a novel agent for multiple myeloma.
    Redic K
    J Pharm Pharmacol; 2013 Aug; 65(8):1095-106. PubMed ID: 23837578
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Carfilzomib and pomalidomide: recent advances in the treatment of multiple myeloma.
    Highsmith KN; Chen SE; Horowitz S
    Pharmacotherapy; 2014 Sep; 34(9):927-40. PubMed ID: 25044413
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Renal thrombotic microangiopathy and podocytopathy associated with the use of carfilzomib in a patient with multiple myeloma.
    Hobeika L; Self SE; Velez JC
    BMC Nephrol; 2014 Sep; 15():156. PubMed ID: 25267524
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Carfilzomib: A new proteasome inhibitor for relapsed or refractory multiple myeloma.
    Steele JM
    J Oncol Pharm Pract; 2013 Dec; 19(4):348-54. PubMed ID: 23292972
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Incidence and management of renal adverse events in patients with relapsed and/or refractory multiple myeloma treated with single-agent carfilzomib.
    Shah JJ
    Oncology (Williston Park); 2013 Dec; 27 Suppl 3():19-23. PubMed ID: 25184232
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Tumor lysis syndrome (TLS) following fludarabine therapy for chronic lymphocytic leukemia (CLL): case report and review of the literature.
    Hussain K; Mazza JJ; Clouse LH
    Am J Hematol; 2003 Mar; 72(3):212-5. PubMed ID: 12605395
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Fatal pulmonary toxicity due to carfilzomib (Kyprolis™).
    Lataifeh AR; Nusair A
    J Oncol Pharm Pract; 2016 Oct; 22(5):720-4. PubMed ID: 26044587
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Recurrent chemotherapy-induced tumor lysis syndrome (TLS) with renal failure in a patient with chronic lymphocytic leukemia - successful treatment and prevention of TLS with low-dose rasburicase.
    Hummel M; Buchheidt D; Reiter S; Bergmann J; Adam K; Hehlmann R
    Eur J Haematol; 2005 Dec; 75(6):518-21. PubMed ID: 16313266
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Super-acute onset of tumor lysis syndrome accompanied by hypercytokinemia during treatment of Hodgkin's lymphoma with ABVD chemotherapy.
    Suzuki T; Takeuchi M; Saeki H; Yamazaki S; Koga H; Abe D; Nishimura M; Nakaseko C; Nakasa H; Nakamura H; Ariyoshi N; Kitada M
    Clin Ther; 2010 Mar; 32(3):527-31. PubMed ID: 20399989
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Rasburicase for the management of tumor lysis syndrome in neonates.
    McNutt DM; Holdsworth MT; Wong C; Hanrahan JD; Winter SS
    Ann Pharmacother; 2006; 40(7-8):1445-50. PubMed ID: 16868218
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 22.